Lasa Supergenerics Limited — Board Meeting, 13-02-2025: Outcome of Board Meeting

The Board of Directors of Lasa Supergenerics Limited has approved the unaudited financial results for the quarter ended December 31, 2024. The results indicate a cautious approach towards advances made to certain parties, with provisions for doubtful advances reflected in the financials. Additionally, the Limited Review Report from the Statutory Auditor was reviewed. The company continues to work on recovering disputed amounts, demonstrating an ongoing engagement with operational challenges. This reflects strategic efforts to maintain financial stability amidst complexities in receivables.